ID   U251-TR3
AC   CVCL_1G29
SY   A172TR3; TR3
DR   BioSample; SAMN06481106
DR   cancercelllines; CVCL_1G29
DR   Cosmic; 1236361
DR   Wikidata; Q54973630
RX   DOI=10.1158/1078-0432.CCR-13-1821;
RX   PubMed=19584161;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Misidentified. Originally thought (PubMed=19584161) to be a A-172 (Cellosaurus=CVCL_0131) derivative but shown to be a U-251MG derivative (DOI=10.1158/1078-0432.CCR-13-1821).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00523.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:72564; Temozolomide (TMZ).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Brain, parietal lobe; UBERON=UBERON_0001872.
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0021 ! U-251MG
SX   Male
AG   75Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 05-10-23; Version: 21
//
RX   DOI=10.1158/1078-0432.CCR-13-1821;
RA   Yip S., Miao J.-Y., Cahill D.P., Iafrate A.J., Aldape K., Nutt C.L.,
RA   Louis D.N.;
RT   "Corrections: MSH6 mutations arise in glioblastomas during temozolomide
RT   therapy and mediate temozolomide resistance.";
RL   Clin. Cancer Res. 19:4543-4544(2013).
//
RX   PubMed=19584161; DOI=10.1158/1078-0432.CCR-08-3012;
RA   Yip S., Miao J.-Y., Cahill D.P., Iafrate A.J., Aldape K., Nutt C.L.,
RA   Louis D.N.;
RT   "MSH6 mutations arise in glioblastomas during temozolomide therapy and
RT   mediate temozolomide resistance.";
RL   Clin. Cancer Res. 15:4622-4629(2009).
//